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ABSTRACT
Inthisstudy,weclarifiedthemolecularmechanism(s)
underlyingtheregulationofmatrixmetalloproteinase
(MMP)-1 gene by hepatocyte growth factor (HGF) in
cultured human dermal fibroblasts. HGF induced
MMP-1 protein as well as mRNA at a transcriptional
level via extracellular signal-regulated kinase (ERK)
signalingpathway.TheregionintheMMP-1promoter
mediating the inducible responsiveness to HGF,
defined by the transient transfection analysis of the
serial50 deletionconstructs,containedanEtsbinding
site. Mutation of this Ets binding site abrogated the
HGF-inducible promoter activity. Ets1 up-regulated
the expression of MMP-1 promoter activity, whereas
Fli1hadantagonisticeffectsonthem.AfterHGFtreat-
ment,theproteinlevelandthebindingactivityofEts1
wasincreasedandthoseofFli1wasdecreased,which
were canceled by PD98059. These results suggest
thatHGFup-regulatesMMP-1expressionviaERKsig-
naling pathway through the balance of Ets1 and Fli1,
whichmaybeanovelmechanismofregulatingMMP-1
gene expression.
INTRODUCTION
Hepatocyte growth factor (HGF), originally identiﬁed as a
potent mitogen for hepatocytes and also known as a ‘scatter
factor’,isa multifunctionalmediator that shows mitogenicand
morphogenetic activities in a variety of cells (1–7).
Recently, HGF has been shown to reverse ﬁbrogenic pro-
cesses, including hepatic ﬁbrosis (8–11).In these reports, HGF
inhibited extracellular matrix deposition and successfully
reduced the amount of preexisting extracellular matrix
constituents, including ﬁbrillar collagens. Most of these
reports demonstrated effects of HGF on tissue ﬁbrosis in an
animal model, butitseffectsonnormalhumancellsinvitro are
poorly investigated. Thus, the mechanism by which HGF acts
against ﬁbrogenesis is not fully understood. However, one of
the anti-ﬁbrogenic effects of HGF is thought to be expressed
by the induction of matrix metalloproteinases (MMPs) (9–11).
Notably, MMP-1, a collagenase which mainly digests inter-
stitial collagens type I and III, is reported to be up-regulated by
HGF in several cell types (12,13).
Earlier investigations demonstrated that HGF induces
MMP-1 via the transcription factor Ets1 in human hepatic
stellate cell line (13). In their study, HGF increases Ets1 pro-
tein level and their binding activity. MMP-1 promoter activity
is dose-dependently stimulated by the co-transfection of Ets1.
The treatment of the HGF-exposed cells with antisense oligo-
nucleotides against Ets1 prevents an HGF-induced increase of
Ets1 and MMP-1 mRNA expression, showing that Ets1 was
essential for the regulation of MMP-1 expression by HGF in
this cell line. In this study, we showed that Fli1, Ets family
transcriptional factor same as Ets1, is also involved in this
HGF-mediated MMP-1 up-regulation in human dermal ﬁbro-
blasts. We also demonstrated that the MMP-1 gene expression
is controlled by the balance of Ets1 and Fli1 on Ets binding
sites (EBS) of this promoter.
MATERIALS AND METHODS
Reagents
Recombinant human HGFs were obtained from R & D
systems (Minneapolis, MN). Actinomycin D, cycloheximide
andantibodyforb-actinwerepurchasedfromSigma(StLouis,
MO). LY294002 and PD98059 were purchased from
Calbiochem (La Jolla, CA). Anti-phospho-extracellular
signal-regulated kinase (ERK), ERK2, Ets1, Fli1 and c-jun
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doi:10.1093/nar/gki648antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). FuGENE 6 was obtained from Roche Diagnostics
(Indianapolis, IN).
Cell cultures
Fibroblasts were obtained by skin biopsy of healthy donors.
All biopsies were obtained with informed consent, institu-
tional review board approval and written informed consent
according to the Declaration of Helsinki. Primary explant
cultures were established in 25 cm
2 culture ﬂasks in MEM
supplemented with 10% fetal calf serum (FCS), 2 mM glutam-
ine and 50 mg/ml gentamycin, as described previously (14,15).
Monolayer cultures were maintained at 37 Ci n5 %C O 2 in air.
Fibroblasts between the third and sixth subpassages were used
for experiments.
Immunoblotting
Dermal ﬁbroblasts were cultured until they were conﬂuent.
Cells were serum-starved in MEM and 0.1% BSA for 24 h
before the cytokine treatment. After incubation with the indic-
ated reagent, the condition medium was collected. Remaining
cells were washed twice with cold phosphate-buffered
saline and lysed in lysis buffer (10 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% NP-40, 50 mM sodium
ﬂuoride, 1 mM phenylmethylsulfonyl ﬂuoride, 1 mM sodium
orthovanadate, 1 mg/ml leupeptin, 1 mg/ml aprotinin and
1mg/ml pepstatin).Aliquots of conditioned media(normalized
for cell numbers) or cell lysates (normalized for protein con-
centrations as measured by the Bio-Rad reagent) were subjec-
ted to electrophoresis on SDS–polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes
were blocked for 1 h and incubated overnight at 4 C with
anti-type I collagen, MMP-1, TIMP-1, TIMP-2, Ets1, Fli1
or b-actin antibody. The membranes were washed in Tris-
buffered saline and 0.1% Tween-20, incubated with secondary
antibodies and washed again. The detection was performed
using the Enhanced Chemiluminescence Detection system
(Amersham, Arlington Heights, IL).
For immunoblotting using antibodies against phospho-
ERK, membranes were incubated with anti-phospho-ERK
monoclonal antibody overnight at 4 C. As a loading control,
immunoblotting was also performed using antibodies
against ERK2.
MMP-1 activity assay
The active MMP-1 level was determined using the MMP-1
Biotrak activity assay system (Amersham, Arlington Heights,
IL), according to the manufacturer’s directions (16). Brieﬂy,
anti-MMP-1 antibodies were precoated onto microtiter wells.
Cultured medium was added to each well, and incubation
conducted at 4 C overnight. The wells were washed and
the absorbance at 405 nm was measured before and after
the incubation with a speciﬁc chromogenic peptide substrate
for 1.5 h. The concentration of active MMP-1 in each sample
was determined by interpolation from a standard curve.
RNA preparation and the northern blot analysis
Total RNA was extracted using an acid guanidinium
thiocyanate–phenol–chloroform method and analyzed by the
northern blotting, as described previously (14,15). RNA was
subjected to electrophoresis on 1% agarose/formaldehyde
gels and blotted onto nylon ﬁlters (Roche Diagnostics,
Indianapolis, IN). The ﬁlters were UV cross-linked, prehybrid-
ized and sequentially hybridized with cDNA probes. The
following cDNA probes were used: human MMP-1 XhoI frag-
ment and GAPDH HindIII–NotI fragment. The membranes
were then washed and exposed to X-ray ﬁlm.
DNA affinity precipitation assay
Oligonucleotides containing biotin on the 50-nucleotide of
the sense strand were used in the assays. The sequence of
each oligonucleotide is as follows: (i) MMP1-EBS oligo,
50-CTATTCATAGCTAATCAAGAGGATGTTATAAAGC-
ATGAGTCAGAC, which corresponds to positions bp  107
to  63 of the human MMP-1 promoter; (ii) MMP1-EBS-M
oligo, 50-CTATTCATAGCTAATCAAGAGTATGTTATA-
AAGCATGAGTCAGAC, lacking the EBS, which is able
to bind the Ets family of transcription factors. These oligo-
nucleotides were annealed to their respective complementary
oligonucleotides, and double-stranded oligonucleotides were
gel-puriﬁed and used. Cell lysates were obtained using lysis
buffer (17). Poly (dI–dC) competitor was incubated with
the cell lysates, followed by incubation with each double-
stranded oligonucleotide. After incubation, streptavidin–
agarose (Sigma) was added to the reaction and incubated.
The protein–DNA–streptavidin–agarose complex was
washed and loaded onto a SDS–polyacrylamide gel. Detec-
tion of c-jun, Ets1 or Fli1 was performed with anti-c-jun, Ets1
or Fli1 antibodies.
Plasmids
The full-length clone of the human MMP-1 promoter contain-
ing fragments of promoter DNA linked to the luciferase
reporter was kindly provided by Dr Constance E. Brinckerhoff
(18). The deletion constructs were generated by PCR using
MMP-1 as a template and substitution mutations were gener-
ated using Quick Change site-directed mutagenesis kits
(Stratagene) and conﬁrmed by sequencing (18). Expression
vector for Ets1 or Fli1 were kindly provided by Dr Maria
Trojanowska (19). And Fli/W321R mutants harboring a single
amino acid mutation in the Ets domain that abolishes its ability
to bind the DNA and a Fli1 dominant interference mutant
containing only the Ets domain (Fli/DBD) were also kindly
provided by Dr Maria Trojanowska (20–22). Plasmids used in
the transient transfection assays were puriﬁed twice on cesium
chloride gradients, as described previously (15). At least two
different plasmid preparations were used for each experiment.
The transient transfection
Fibroblasts were grown to 50% conﬂuence in 100 mm dishes
in MEM with 10% FCS. The medium was replaced with
serum-free medium, and ﬁbroblasts were transfected with
the MMP-1 promoter constructs, expression vectors or corres-
ponding empty constructs, employing FuGENE6 as described
previously (23). In order to correct minor variations in trans-
fection efﬁciency, pSV-b-galactosidase vector (Promega,
Madison, WI) was included in all transfections. After 48 h
of incubation, the cells were harvested in 0.25 M Tris–HCl
(pH 8) and fractured by freeze-thawing. Extracts, normalized
for protein content as measured by the Bio-Rad reagent, were
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14C]-chloramphenicol for
90 min at 37 C. Butylated chloramphenicol was extracted
using an organic solvent (2:1 mixture of tetramethylpenta-
decane and xylene) and quantitated by scintillation counting.
The data were standardized with b-galactosidase activities.
Each experiment was performed in duplicate.
Statistical analysis
Statistical analysis was carried out with the Mann–Whitney
test for comparison of means. P-values < 0.05 were con-
sidered signiﬁcant.
RESULTS
The effects of HGF on the expression of MMP-1 protein
or mRNA in normal dermal fibroblasts
To examine ﬁbrogenic/ﬁbrolytic protein expression by HGF in
normal ﬁbroblasts, we determined the dose-dependent effect
of HGF on the protein levels of MMP-1, TIMP-1 or TIMP-2.
The MMP-1 protein level in cell lysates was up-regulated by
the treatment with 10 ng/ml HGF maximally in dermal
ﬁbroblasts (Figure 1A). On the other hand, the production
of TIMP-1 or -2 protein was not increased by the HGF
simulation compared with the levels in untreated cells. Spe-
ciﬁc enzyme-linked immunosorbent assays revealed that
HGF also increased MMP-1 catalytic activity in the cultured
media (Figure 1B).
Moreover, the MMP-1 mRNA expression was also elevated
signiﬁcantly after the stimulation with HGF for 12 h, sustained
until 48 h later (Figure 1C). Thus, the effect of HGF on the
MMP-1 protein level paralleled that on the mRNA level.
Mechanisms of the HGF-mediated MMP-1
up-regulation
To establish whether the increase in the MMP-1 levels after
HGF treatment involves the synthesis of new proteins or the
transcriptional activation, we tested the magnitude of MMP-1
induction in the presence of cycloheximide (protein synthesis
inhibitor) or actinomycin D (RNA synthesis inhibitor).
Cycloheximide did not block the HGF-mediated up-regulation
of MMP-1 protein expression, whereas actinomycin D
signiﬁcantly blocked this up-regulation (Figure 2A). In addi-
tion, we wished to determine whether HGF increases the sta-
bility of MMP-1 mRNA. Following the inhibition of
transcription, the loss of MMP-1 mRNA induced by HGF
was not signiﬁcantly different from that observed in the
untreated cells (Figure 2B). The failure of HGF to increase
the half-life of MMP-1 mRNA suggests that the HGF-
mediated induction of the MMP-1 expression is regulated at
the level of transcription. Taken together,these results indicate
that HGF up-regulates the MMP-1 expression at the transcrip-
tional level and this induction is independent of new protein
synthesis.
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Figure 1. The effects of HGF on the MMP-1 expression. (A) To examine the
dose-dependency of the effect of HGF on the expression of MMP-1 protein,
human dermal fibroblasts were cultured until they were confluent, and then
incubated for an additional 24 h under conditions of serum starvation. Cells
were incubated in serum-free medium for 72 h in the absence or presence of
HGF at the indicated doses before the protein extraction. Aliquots were sub-
jected to immunoblotting with anti-MMP-1, -TIMP-1 or -TIMP-2 antibodies.
Thesamemembranewasthenstrippedandreprobedwithanti-b-actinantibody
asaloadingcontrol.(B)Cellswereincubatedinserum-freemediumfor72hin
the presence or absence of HGF at the indicated doses before collection of the
medium. Specific enzyme-linked immunosorbent assays for detecting active
MMP-1 levels were performed as described in ‘Materials and Methods’.
*P < 0.05 as compared with the value in untreated cells. (C) Cultured fibro-
blasts were incubated in the presence or absence of 10 ng/ml HGF under the
sameconditionsfortheindicatedtimecourses,andthenorthernblotanalysisof
MMP-1 mRNA expression was performed. Levels of GAPDH mRNA are
shownasaloadingcontrol.Oneexperimentrepresentativeofthreeindependent
experiments is shown. MMP-1 mRNA levels quantitated by scanning densi-
tometry and corrected for the levels of GAPDH in the same samples are shown
relative to the level in untreated cells (1.0). Data are expressed as the
mean – SD of three independent experiments. *P < 0.05 as compared with
the value in untreated cells.
3542 Nucleic Acids Research, 2005, Vol. 33, No. 11PD98059 inhibits the HGF-mediated up-regulation
of MMP-1 protein and mRNA
We investigated whether ERK or phosphoinositide 3-kinase
(PI3K) activation is involved in the HGF-mediated MMP-1
protein or mRNA induction. Pretreatment of cells with
mitogen-activated protein kinase (MAPK)/ERK inhibitor,
PD98059, blocked HGF-mediated up-regulation of MMP-1
protein in a dose-dependent manner, whereas PI3K inhibitor,
LY294002 did not (Figure 3A). The pretreatment of cells with
PD98059 also blocked the HGF-mediated up-regulation of
MMP-1 mRNA (Figure 3B). These results suggest that
HGF regulates MMP-1 expression through ERK signaling
in human dermal ﬁbroblasts.
ERK signaling pathway is activated following
HGF treatment
We investigated whether HGF treatment induces the ERK
phosphorylation in human dermal ﬁbroblasts. Immunoblotting
using anti-phospho-ERK antibody revealed a signiﬁcant phos-
phorylation of ERK after 5 min of treatment with HGF, and
this increase was sustained until 60 min (Figure 4A). Immun-
oblotting for total ERK protein demonstrated that the amount
of ERK did not signiﬁcantly change in the presence of HGF.
In addition, we investigated the role of ERK signaling path-
way in the transcriptional regulation of MMP-1. HGF induced
the activity of MMP-1 full-length  4372 to +63 bp promoter
construct (3.1-fold). And PD98059 signiﬁcantly blocked the
HGF-mediated MMP-1 promoter activity in a dose-dependent
manner (Figure 4B). These results suggest that ERK signal-
ing pathway participates in the regulation of MMP-1 gene
by HGF.
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Figure 2. EffectsofactinomycinDorcycloheximideonHGF-mediatedMMP-
1 mRNA up-regulation. (A) Human dermal fibroblasts were serum-starved for
24 h and pretreated with 10 mg/ml cycloheximide or 2.5 mg/ml actinomycin D,
for 1 h before the addition of 10 ng/ml of HGF for 24 h. Cell lysates were
subjected to immunoblotting with anti-MMP-1 antibodies. The same mem-
brane was then stripped and reprobed with anti-b-actin antibody as a loading
control. One experiment representative of three independent experiments is
shown. MMP-1 protein levels quantitated by scanning densitometry and cor-
rectedforthelevelofb-actininthesamesamplesareshownrelativetothelevel
inuntreatedcells(1.0).*P < 0.05ascomparedwiththevalueinuntreatedcells.
CHX, cycloheximide;AcD, actinomycin D.(B) The Effectof HGFon MMP-1
mRNA half-life was examined. Human dermal fibroblasts were serum-starved
for 24 h and incubated in the absence or presence of 10 ng/ml HGF for 12 h
before the addition of 2.5 mg/ml actinomycin D. RNA was extracted from the
cells at the indicated time after actinomycin D administration. MMP-1 mRNA
expressionwasdeterminedby thenorthernblotanalysis.Thecorrecteddensity
by GAPDH levels was expressed as a percent of the value at time 0 and plotted
on a scale. The solid line indicates the HGF-treated levels, and the dotted line
indicates control (untreated) levels.
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Figure 3. Effects of LY294002 and PD98059 on the HGF-induced MMP-1
expression (A) Human dermal fibroblasts were serum-starved for 24 h and
pretreated with 10 or 30 mM LY294002, or 10 or 20 mM PD98059, for 1 h
before the addition of 10 ng/ml of HGF for 72 h. Conditioned medium were
subjected to immunoblotting with anti-MMP-1 antibodies. (B) The northern
blotanalysisofMMP-1mRNAexpressionwasperformed.LY294002(30mM)
or PD98059 (20 mM) was added 1 h before the addition of 10 ng/ml of HGF.
After 24 h, cells were collected. Levels of GAPDH mRNA are shown as a
loading control. MMP-1 mRNA levels quantitated by scanning densitometry
and corrected for the level of GAPDH in the same samples are shown relative
to the levels in untreated cells (1.0). One experiment representative of three
independent experiments is shown. *P < 0.05 as compared with the value in
untreated cells.
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up-regulation by HGF
To identify potential regulatory elements of the human MMP-
1 gene by HGF, we performed the transient transfection assays
using a series of 50-deletions of the MMP-1 promoter linked to
the luciferase reporter gene. The full-length bp  4372 to +63
construct and the shorter constructs with deletion end point at
bp  1600 to +63 and bp  512 to +63 responded to the HGF
stimulation to the same extent. The corresponding empty con-
structsshowedlittle reactivitytoHGF.These dataindicate that
the HGF-responsive element is localized between bp  512
and +63 in the MMP-1 promoter (Figure 5).
This region of MMP-1 promoter has a EBS (from bp  87 to
 84) as well as AP-1 binding site, and MMP-1 gene is shown
to be regulated by Ets1 as described above (13). The effects of
substitution mutations changing GGAT to GTAT in the EBS
of MMP-1 gene were investigated (Figure 5). Mutating the
EBS resulted in the signiﬁcant reduction of the promoter
activity induced by HGF. Thus, the integrity of the EBS of
MMP-1 promoter is critical for the HGF effect on the MMP-1
expression.
Ets1 and Fli1 have antagonistic effects on the MMP-1
promoter and compete with each other in the regulation
of the MMP-1 promoter activity
To explore whether Ets family transcriptional factors are
involved in the up-regulated MMP-1 expression by HGF,
the bp  4372 to +63 MMP-1 construct was co-transfected
with increasing amounts of expression vectors of Ets1 and
Fli1. The overexpression of Ets1 remarkably induced the
promoter activity. In contrast to Ets1, Fli1 down-regulated
the MMP-1 promoter activity and Fli1 abolishes the Ets1-
mediated MMP-1 promoter activation in dermal ﬁbroblast,
competing with each other (Figure 6A).
Next, the effects of the overexpression of two Fli1 mutants
on the MMP-1 promoter were investigated (Figure 6B). In
comparison with the wild-type Fli1, both mutants caused
less but signiﬁcant decreases in the MMP-1 promoter activity,
suggesting that direct (via DNA binding) and indirect (via
protein–protein interaction) mechanisms contribute to the
effects of Fli1 on the MMP-1 promoter.
In addition, we determined whether the forced overexpres-
sion of Ets1 or Fli1 can enhance the MMP-1 protein induction.
Immunoblotting revealed that the transient transfection of
Ets1 led to the induction of the MMP-1 protein expression
(Figure 6C), whereas those of Fli1 had the opposite effect on
the MMP-1 protein expression. These data conﬁrmed that both
Ets1 and Fli1 can regulate the MMP-1 expression.
The balance of Ets1 and Fli1 is associated with MMP-1
up-regulation by HGF
First, we examined whether HGF altered the amounts of Ets1
or Fli1 in cell lysates. Immunoblotting revealed that the
amounts of Ets1 were increased by the HGF stimulation,
whereas Fli1 proteins were decreased after the stimulation
with HGF for 3 h, compared with the level in control cells
(Figure 7A). Furthermore, we investigated whether the ERK
activation is involved in the HGF-mediated Ets1 or Fli1 pro-
tein induction or reduction. Pretreatment of cells with
PD98059 blocked the HGF-mediated regulation of Ets1 or
Fli1 protein in a dose-dependent manner (Figure 7B).
Taken together, these results indicate that HGF up-regulates
the MMP-1 expression via the alteration of the levels of Ets1
and Fli1 through ERK signaling pathway.
Furthermore, we performed DNA afﬁnity precipitation
assay using MMP1-EBS oligo, containing the EBS of the
MMP-1 promoter. As a negative control, we used MMP1-
EBS-M oligo. The results showed that only the MMP1-EBS
oligo bound endogenous Ets1 strongly after HGF treatment for
3 h, whereas Fli1 binding to EBS was decreased (Figure 7C).
MMP1-EBS-M oligo didnotbind these transcriptional factors.
MMP1-EBS oligo also contains AP-1 binding sequence (bp
 72 to  66). To note, our result showed that the binding
activity of c-jun, which is one of the AP-1 transcription factors
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Figure 4. Activation of ERK signaling pathway by HGF in human dermal
fibroblasts. (A) Cell lysates (30 mg of protein/sample) were subjected to
immunoblotting with anti-phospho-ERK antibody. That the amounts of
ERK proteins were unchanged was confirmed by immunoblotting using
anti-ERK2 antibodies. One experiment representative of three independent
experiments is shown. The levels of phosphorylated ERK quantitated by scan-
ningdensitometryandcorrectedforthelevelsoftotalERKinthesamesamples
areshownrelativetothelevelofuntreatedcells(1.0).Dataareexpressedasthe
mean – SD of three independent experiments. (B) Human dermal fibroblasts
were transiently transfected with the full-length MMP-1 promoter. After
incubation overnight, the cells were pretreated with either vehicle alone (con-
trol), 10 or 30 mM LY294002, or 10 or 20 mM PD98059 for 1 h before the
addition of HGF. Cells were incubated in the absence (open bars) or presence
(closedbar)of10ng/mlHGFforadditional24h.ThegraphdepictstheMMP-1
promoter activities, and the basal promoter activitywas arbitrarilyset at 1. The
number shows the promoter activities stimulated by HGF relative to the pro-
moterwithoutHGF.Dataareexpressedasthemean – SDofthreeindependent
experiments. *P < 0.05 as compared with the value in untreated cells.
3544 Nucleic Acids Research, 2005, Vol. 33, No. 11regulating MMP-1 expression and was reported to be induced
by HGF (13,24,25), was also inhibited by the mutation of
EBS. These results suggest that the exchange of Fli1 with
Ets1 on the promoter by HGF regulates the induction of
MMP-1 promoter activity.
We have recently reported that HGF induces MMP-1
expression and activity in ﬁbroblasts from both normal sub-
jects and scleroderma (SSc) patients, but that the HGF-treated
MMP-1 level in SSc ﬁbroblasts was overexpressed more
apparently than in normal ﬁbroblasts, which is probably a
result of the overexpression of HGF receptor (c-met) in SSc
ﬁbroblasts (26). Finally, we investigated whether Ets1 or Fli1
also contribute to the hyperreactivity of MMP-1 expression to
HGF in SSc ﬁbroblasts. As shown in Figure 7D and E, basal
Fli1 protein expression is consistently down-regulated in SSc
dermal ﬁbroblasts, whereas there is no difference in Ets1 pro-
tein expression between normal and SSc ﬁbroblasts, which
was consistent with a previous report (27). On the other
hand, the HGF-treated Ets1 or Fli1 level in SSc ﬁbroblasts
was up- or down-regulated more dramatically (3.71- and
0.13-fold) than in normal ﬁbroblasts (2.95- and 0.32-fold),
respectively. This result suggested that the EBS is equally
important for the hyperreactivity of MMP- 1 expression to
HGF stimulation in SSc ﬁbroblasts.
DISCUSSION
Our study showed that HGF induced the MMP-1 expression at
the transcriptional level. Treatment of the cells with PD98059
inhibited HGF effect on MMP-1 expression. The region in the
MMP-1 promoter mediating the inducible responsiveness to
HGF, deﬁned bythe transient transfectionanalysisofthe serial
50 deletion constructs, contained the EBS.
The Ets transcription factor family was originally identiﬁed
asahumanhomologofviraloncogene,which was identiﬁed in
E26 avian erythroleukemia virus (28), including >30 currently
known members. All posses a conserved region termed the Ets
domain, which recognizes and binds to GGA(A/T) purine-rich
core sequences that can function as the EBS (29).
Many MMP genes including MMP-1 and MMP-13 contain
the EBS in their regulatory region, often combined with an
AP-1-binding site to form a responsive complex. Multiple
EBS have been identiﬁed in the MMP-1 promoter region
(30–32), but the EBS that is important in regulating MMP-1
expression is not known. Furthermore, Ets1 has been shown to
modulatetranscriptionoftheseMMPgenes,includingMMP-1
(24,32); there has been no report that discussed the involve-
ment of Fli1 in the gene regulation of MMP-1. Our results
suggested that HGF increases MMP-1 promoter activity
through increased expression and binding activity of Ets1
and decreased those of Fli1, which was canceled by
PD98059, and that MMP-1 gene expression is regulated by
the balance of Ets1 and Fli1. Interestingly, Ets1 and Fli1 have
opposite effects on the a2(I) collagen gene expression, and
Fli1inhibitsthea2(I)collagenpromoteractivitybycompeting
with Ets1 (33), although the exchange of Fli1 with Ets1 on the
promoter is not examined. Similar phenomenon was shown in
the MMP-1 promoter inthis study. Taken together,the balance
-4372
vector
+63
-1600
+63
-512
+63
2
Basal level
4
Fold induction
Fold induction
by HGF
1.1 ±0.20
2.9 ±0.30*
3.2 ±0.14*
3.0 ±0.28*
100
530 ±16.8
544±20.7
1410.1±72.3
-4372
+63
1.3 ±0.39 99.1±6.1
*
*
*
EBS-mutated
Figure 5. Identification of the MMP-1 promoter region mediating HGF stimulation. The indicated MMP-1 promoter deletion constructs, the corresponding empty
constructorthemutatedconstruct(EBS-mutated)weretransfectedintheabsenceorpresenceof10ng/mlHGF.Thebargraphandthenumberontheleftrepresents
foldstimulationofthepromoteractivitystimulatedbyHGFrelativetothepromoteractivitywithoutHGF,whichwasarbitrarilysetat1.Thenumberontherightshow
the basal levels (i.e. without HGF) of each construct relative to the corresponding vector, which was arbitrarily set at 100%. Mean – SD from four independent
experimentsarepresented.Asteriskindicatesstatisticallysignificantresultscomparedwiththebasalpromoteractivitiesofeachconstruct(P < 0.05,Mann–Whitney
U-test).
Nucleic Acids Research, 2005, Vol. 33, No. 11 3545of Ets1 and Fli1 may be a novel mechanism in regulating the
MMP-1 gene expression. Furthermore, a previous study repor-
ted that Ets transcription factors mostlyact in concertwith AP-
1 to regulate MMP-1 expression, and that the binding activity
of c-jun to AP-1 binding sequence in the human MMP-1
promoter was increased by HGF stimulation (13). Our
study indicated that effect of HGF on the binding activity
of c-jun was inhibited by the mutation of EBS. Thus, EBS
may be also important for the gene regulation by AP-1,
probably through the modiﬁcation of chromatin structure.
The association between HGF and ERK, between ERK and
Ets family, between ERK and MMP-1 or between Ets family
and MMP-1 has been well described previously (13,33–38).
However, our study clariﬁed the overall regulatory mechanism
of MMP-1 by HGF in human dermal ﬁbroblasts.
HGF is expected to express anti-ﬁbrotic effect in various
organs. SSc is an acquired disorder, which typically results in
ﬁbrosis of the skin and internal organs (39). Fibroblasts from
the affected SSc skin cultured in vitro produce excessive
amounts of various collagens, mainly type I and type III
collagens (40,41), and display increased transcriptional activ-
ities of the corresponding genes (42,43). The basal expression
of TIMP-1 was increased whereas those of MMP-1 as well as
MMP-2 and MMP-3 is reduced in SSc ﬁbroblasts compared
with ﬁbroblasts of normal subjects (44,45). Thus, the balance
of the synthesis and decomposition of collagen is thought to
play an important role in the pathogenesis of this disease, and
the induction of MMP-1 may be a reliable approach to the
treatment of SSc. On the other hand, despite its anti-ﬁbrotic
properties, the serum level of HGF is reported to be markedly
increased in SSc (46). Immunocytochemical staining or
immunoblotting revealed that c-met was overexpressed in
SSc ﬁbroblasts (26,47). These ﬁndings are inconsistent with
MMP-1 down-regulation in SSc ﬁbroblasts. This contradiction
may be explained by the ﬁnding that serum HGF levels in SSc
were much lower than those used in our study, suggesting that
the increase in serum HGF levels is insufﬁcient to regulate
MMP-1 expression in SSc ﬁbroblasts (47). We have recently
reported that HGF had stronger effects on MMP-1 induction in
SSc ﬁbroblasts than in normal ﬁbroblasts, probably due to the
overexpression of c-met in SSc ﬁbroblasts (26). In this study,
the HGF-treated Ets1 or Fli1levelinSScﬁbroblastswas up-or
down-regulated more dramatically than in normal ﬁbroblasts,
respectively, which may be also a result of the overexpression
of c-met in SSc ﬁbroblasts. This result suggested that the EBS
plays a role in the hyperreactivity of MMP-1 expression to
HGF stimulation in SSc ﬁbroblasts.
Figure 6. The effects of overexpressed Ets1 or Fli1 on the MMP-1 promoter
activity (A) Human dermal fibroblasts were transiently co-transfected with the
MMP-1 promoter construct (1.5 mg) and either Fli1 or Ets1 was added indivi-
dually orwitha constantamountofEts1expressionvectoraddedtogetherwith
increasing amounts of Fli1 expression vector. To ensure an equal amount of
co-transfectedexpressionvectorsundereachcondition,appropriateamountsof
corresponding vector were added to individual co-transfections. The bar graph
represents the fold induction of the MMP-1 promoter activity co-transfected
withFli1orEts1individuallyortogetherrelativetotheactivityofthepromoter
co-transfected with corresponding vector, which was arbitrarily set at 1.
Mean – SD from four independent experiments are presented. (B) The tran-
sient transfections were performed with Fli1 DNA binding mutant (Fli/
W321R), Fli1 dominant interference mutant (Fli/DBD) and the MMP-1 pro-
moter construct. The Fli1 DNA binding mutant contains a single amino acid
mutation that abolishes DNA binding, and the Fli1 dominant interference
mutant contains the Ets domain. (C) The overexpression of the Ets1 or Fli1
in human dermal fibroblasts was performed by the transient transfection as
described in ‘Materials and Methods’. The cell lysates were analyzed by im-
munoblot analysis. The same membrane was then stripped and reprobed with
anti-b-actin antibody to show as a loading control. The levels of type I pro-
collagenquantitatedbyscanningdensitometryandcorrectedforthelevelsofb-
actin are shown relative to the level of cells transfected with vector (1.0). Data
are expressed as the mean – SD of three independent experiments. *P < 0.05
as compared with the value in untreated cells.
3546 Nucleic Acids Research, 2005, Vol. 33, No. 11Currently, several investigators have reported a therapeutic
effect of cyclophosphamide, prednisolone or methotrexate
therapy on the ﬁbrosis of SSc (48,49). However, their
approach seems to be initiated at the early stage of SSc, before
the ﬁbrosis begins to develop. Our study raises the possibility
of the clinical use of HGF that it can improve dermal sclerosis
in the chronic stage. Further investigation of the effects of
HGF on collagen metabolism may contribute to the treatment
of ﬁbrosis in SSc.
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